Vote Scores

Home / Companies / Arcturus Therapeutics Holdings Inc. / 5 Jun 2026

Meeting · year to 30 June 2026209 filers reporting

Arcturus Therapeutics Holdings Inc.: meeting of 5 Jun 2026

Votes reported on Form N-PX, item by item

209 Form N-PX filers reported votes at the Arcturus Therapeutics Holdings Inc. meeting of 5 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

8 nominees; 94.3% of reported votes for; 14 filers withheld from or voted against at least one nominee.

1,288 vote records from 83 filers. 1 of the 78 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

91.6% for0.0% against8.4% other1.3% against management83 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

346 vote records from 209 filers. 11 of the 193 filers that marked the item either way voted against management. 16 filers reported this item without a management mark.

86.6% for5.7% against7.7% other5.7% against management209 filers98.4% for1.6% against1.4% against management16,672,563 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

161 vote records from 83 filers. 0 of the 78 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

94.0% for0.0% against6.0% other0.0% against management83 filers100.0% for0.0% against0.0% against management7,603,515 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalForForFor
State Street and SPDRForForFor
American CenturyForAgainst *For
InvescoForForFor
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsForForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertForForFor
J.P. MorganNo reportForNo report
Goldman SachsForForFor
WisdomTreeForForFor
PGIM and PrudentialForForFor
Jackson National fundsSplit or no voteSplit or no voteSplit or no vote
Northern Trust and FlexSharesSplit or no voteForSplit or no vote
SEIForForFor
T. Rowe PriceForForFor
Lincoln FinancialForForFor
VoyaForForFor
First TrustNo reportForNo report
Russell InvestmentsForForFor
NationwideForForFor
Victory CapitalForForFor
Brighthouse FundsForForFor
Guggenheim and RydexForForFor
Columbia ThreadneedleForForFor
BNY MellonNo reportForNo report
PrincipalForForFor
Pacific Life fundsForForFor
Global XForForFor
MFSForForFor
Federated HermesForForFor
AllianceBernsteinNo reportForNo report
DWSForForFor
AllspringForForFor
Neuberger BermanNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Arcturus Therapeutics Holdings Inc. meeting?

209 Form N-PX filers reported votes at the meeting of 5 Jun 2026. On say-on-pay, 11 of 193 voted against management (5.7%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Arcturus Therapeutics Holdings Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Arcturus Therapeutics Holdings Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Arcturus Therapeutics Holdings Inc. with a meeting date within three days of 5 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.